1.40
1.40 (0%)
As of Feb 14, 2025
Synlogic, Inc. [SYBX]
Source:
Company Overview
Synlogic, Inc. is a biopharmaceutical company that advanced novel therapeutics to transform the care of serious diseases. We focused on rare metabolic disorders, with our lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU).
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | 617-401-9975 |
| Industry | manufacturing |
| CEO | Aoife Brennan |
| Website | www.synlogictx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-41 |
| Net Income | $-23.4 |
| Net Cash | $-6.1 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | -511,875 |
| Profit as % of Revenues | -0% |
| Profit as % of Assets | -49% |
| Profit as % of Stockholder Equity | -183.2% |
Management Effectiveness
| Return on Equity | -183.2% |
| Return on Assets | -117.8% |
| Turnover Ratio | 0% |
| EBITA | $-41 |
Balance Sheet and Cash Flow Measures
| Total Assets | $19.8 |
| Total Liabilities | $7.1 |
| Operating Cash Flow | $-31.7 |
| Investing Cash Flow | $25.3 |
| Financing Cash Flow | $0.2 |
